What's Happening?
Insulet Corporation, a leader in tubeless insulin pump technology, has initiated a pivotal study to advance its fully closed-loop automated insulin delivery system for individuals with type 2 diabetes.
The study, known as the EVOLVE clinical study, is a multi-center randomized control trial that aims to enroll up to 350 adults across 40 U.S. sites. Participants, aged 18 to 75, are living with type 2 diabetes and using insulin. The system, which integrates with a continuous glucose monitor, is designed to manage blood sugar levels without the need for daily injections or fingersticks. This innovation is expected to improve glycemic outcomes and reduce the burden on users by eliminating the need for mealtime interactions. The study follows a series of feasibility studies that showed promising results, including a significant improvement in time in range over standard injection therapy.
Why It's Important?
The development of a fully closed-loop automated insulin delivery system represents a significant advancement in diabetes management, particularly for the estimated 5.5 million people with type 2 diabetes who require insulin. By reducing the need for user interaction and simplifying the management of blood sugar levels, this system could greatly enhance the quality of life for patients. The potential to streamline onboarding and training processes also means that healthcare providers can more easily integrate this technology into primary care settings, where the majority of diabetes management occurs. This could lead to broader adoption of automated insulin delivery systems, which currently remain underutilized despite their benefits.
What's Next?
Insulet plans to continue enrolling participants in the EVOLVE study and aims to submit a 510(k) filing to the FDA in 2027, with a potential launch of the fully closed-loop system in 2028. The company is committed to expanding access to automated insulin delivery systems and is working to increase adoption rates among healthcare providers. As the study progresses, further data will be collected to support the efficacy and safety of the system, potentially influencing future diabetes care standards and practices.
